Cell Pathways CLPA - Neue Testergebnisse - 500 Beiträge pro Seite

[biologist]

Cell Pathways hat soeben neue positive Testergebnisse bzgl. seiner CP461-Versuchsreihe veröffentlicht. Hier die Original-Message:

Link: http://biz.yahoo.com/bw/011009/90124_1.html

Cell Pathways Announces Positive Early Data in Ongoing Chronic Lymphocytic Leukemia Phase IIA Clinical Trial of CP461
HORSHAM, Pa.--(BW HealthWire)--Oct. 9, 2001--

Cell Pathways, Inc., (Nasdaq:CLPA - news) today announced positive early data from a Phase IIa study of its oral investigational drug, CP461, in previously untreated patients with chronic lymphocytic leukemia (CLL). Of 15 patients who received CP461 at a 400 mg total daily dose (200 mg twice daily), 9 patients demonstrated a reduction from baseline in their absolute lymphocyte counts. Notably, 6 of these patients achieved reductions of 30% to 48% in their blood lymphocyte counts. Encouraged by these early indications of anticancer activity, Cell Pathways is entering an additional 6 patients for treatment at a dose of 800 mg (400 mg twice daily) of CP461.

Gruß

biologist

[biologist]

An alle wenigen Cell Pathway-Fans,

heute gibt es von CLPA auf der UBS Warburg Global Life Sciences Konferenz in New York einen Info-Vortrag. Die gestrigen News werden dann wohl auch Erwähnung finden.

Monday October 1, 8:50 am Eastern Time
Press Release
SOURCE: Cell Pathways
Cell Pathways to Present At the UBS Warburg Global Life Sciences Conference
HORSHAM, Pa.--(BW HealthWire)--Oct. 1, 2001--Cell Pathways, Inc. (Nasdaq:CLPA - news) today announced that Robert J. Towarnicki, chairman and chief executive officer, will present at the UBS Warburg Global Life Sciences Conference on Wednesday, October 10, 2001 at 1:00 p.m. eastern time at the Pierre Hotel, New York, NY.

The conference will be available to the public through listen-only telephone conference lines. The participation dial-in numbers are 1-800-500-0177 domestic and 1-719-457-2679 international. An audio replay will be available for four weeks after the conference at 1-800-759-8603 domestic and 1-402-220-8537 international.

cu biologist

[biologist]

News bei Cell Pathways: Versuchsreihe darf fortgesetzt werden. Schlußkurs $8,00 (+32%)

Related Quote
CLPA 7.62 +1.57
delayed 20 mins - disclaimer
Quote Data provided by Reuters



Friday December 7, 3:47 pm Eastern Time
Cell Pathways says FDA clears trial resumption
HORSHAM, Pa., Dec 7 (Reuters) - Cell Pathways Inc. (NasdaqNM:CLPA - news) said on Friday that U.S. regulators have allowed the biotechnology company to resume a late-stage clinical trial testing its Aptosyn drug in combination with cancer treatment Taxotere for patients with non-small cell lung cancer.

The company had halted enrollment of patients in the trial in October after an independent data and safety monitoring board requested a safety analysis of the study.

Cell Pathways said the U.S. Food and Drug Administration had now completed its review of the safety data and authorized the resumption of enrollment.

Gruß

biologist

[biologist]

Einschätzung über Auswirkungen der News bei Cell Pathways:

Nach der Freigabe für eine Fortsetzung der klinischen Tests von Aptosyn + Taxotere (Docetaxel) seitens der FDA (mit sofortiger Wirkung!!!!) ist Cell Pathways wieder oben auf. Immerhin stellt diese Medikamentenkombination momentan CLPA`s wichtigstes Standbein dar, da sie in vier klinischen Testphasen verwendet wird. Von diesen vier Testphasen befindet sich eine bereits in der Endphase der Phase III und steht somit unmittelbar vor der Marktzulassung. Die Medikamentenkombination soll ihre Anwendung bei Lungenkrebserkrankungen finden, womit bei Zulassung ein sehr großer Markt zur Verfügung steht.
Die FDA erlaubte CLPA am 5. Oktober 2001, nach Bekanntgabe des Stopps der klinischen Testphase III, allerdings die Fortführung der Behandlung der 200 Patienten, die sich bereits in dieser Testphase befanden, so daß CLPA nun noch nicht einmal unter Zeitverzug zu leiden hat.
Da die News erst kurz vor Handelsende (3:36 p.m.) heraus gegeben wurden, besteht meiner Meinung nach trotz der schwachen Marktentwicklung am Freitag eine gute Chance, daß CLPA am Montag weiter zulegen wird.

Gruß

biologist

[biologist]

Hier noch ein kleiner Link zu den letzten offiziellen Meldungen und Kursen von Cell Pathways:

http://finance.yahoo.com/q?s=CLPA&d=d


Gruß

biologist

[FLOTSAM_AND_JETSAM_US]

Cell Pathways` Second-generation Compound, CP461, Induces Apoptosis in Leukemic Cells Isolated From Patients With CLL
Compound Subject of Ongoing Phase IIa Clinical Study

HORSHAM, Pa.--(BUSINESS WIRE)--Dec. 10, 2001-- Laboratory research, reported today at the American Society for Hematology (ASH) meeting in Orlando, showed CP461 selectively triggered programmed cell death, or apoptosis, in primary leukemic cell samples from patients with chronic lymphocytic leukemia (CLL). At the same time, the drug had marginal pro-apoptotic effect on normal peripheral blood white cells. These data are supportive of the potential of Cell Pathways, Inc. (Nasdaq:CLPA - news) second-generation selective apoptotic antineoplastic drug (SAAND) as a treatment for CLL. Cell Pathways` collaborators Adam Lerner, M.D. and Eunyi Moon, Ph.D. of Boston University`s Boston Medical Center published the research.

In work done in other cell systems, CP461 and other SAAND compounds have been shown to selectively trigger cell death by apoptosis in abnormally growing cancerous and precancerous cells but not in normal cells by inhibiting certain cyclic GMP phosphodiesterase enzymes (cGMP PDEs). Cell Pathways has shown over-expression of these cGMP PDEs in a wide variety of tumor types.

``Treatment with 30 micromolar CP461 induced greater than 50% apoptosis within 24 hours in 10 of 10 primary leukemic cell samples taken from patients with CLL, while the same drug concentration induced only a marginal 14% apoptosis in normal peripheral blood white cells,`` said Dr. Lerner. ``Researchers have made considerable study in the past of the role of cyclic AMP in leukemic white blood cells. This new study suggests that cyclic GMP pathways may also be involved and merit further study.``

``These preclinical results, among others, prompted us to initiate the ongoing Phase IIa clinical study of CP461 in patients with previously untreated CLL,`` remarked Rifat Pamukcu, M.D., chief scientific officer of Cell Pathways, Inc. ``The preliminary data from the first 15 patients in that trial, reported on October 9th, revealed reductions of up to 48% from baseline in the absolute lymphocyte counts in some of the patients receiving a 400 mg daily dose of CP461 within two to six weeks of treatment. More recently, we continue to be encouraged in that three of these patients have shown reductions of 50% to 80% in their absolute lymphocyte counts. Another patient has shown durability of a hematological response out to 22 weeks of therapy. In the interim, investigators have initiated testing a higher dose of CP461 in additional patients, to investigate any dose-response relationship of CP461 in the treatment of CLL.``

In addition to the direct apoptotic effects of CP461 on the CLL patient isolates, the Boston researchers also observed that the drug blocked cell proliferation in a CLL cell line by inducing G2 arrest in the cycle of cell division. They also noted the disruption of cellular structures called microtubules in the treated leukemic cell line, as well as a change in cell shape.

[FLOTSAM_AND_JETSAM_US]

Cell Pathways Identifies Presence of SAANDs Drug Targets and Mechanism of Apoptosis Induction in Breast Cancer Cells
Results Reported At San Antonio Breast Cancer Symposium

HORSHAM, Pa.--(BW HealthWire)--Dec. 13, 2001--Cell Pathways, Inc. (Nasdaq:CLPA - news) today released data demonstrating the presence, in breast cancer cells, of the cyclic GMP phosphodiesterases (cGMP PDEs) targeted by their selective apoptotic antineoplastic drugs (SAANDs). SAANDs, including Aptosyn(TM) (exisulind) and CP461, inhibit certain cyclic GMP PDEs found to be over-expressed in a variety of tumor types. In doing so, they trigger down-stream pathways leading to programmed cell death, or apoptosis, in the cancer cells. The investigators also demonstrated that inhibition of these cGMP PDEs led to the decrease of another important protein, beta-catenin. The accumulation of beta-catenin within the cell has been implicated in the growth of several types of cancers including, most recently, breast cancer. The new findings were presented today by scientists from Cell Pathways and their collaborators from the University of California at Los Angeles (UCLA) School of Medicine at the annual San Antonio Breast Cancer Symposium.

``While this study confirms the presence of SAANDs targets, cGMP PDEs of the PDE 1 and 5 families, in breast tumor cells, the more important finding is that inhibition of the cGMP PDEs in these breast cancer cells by Aptosyn(TM) and CP461 results in a reduction of the beta-catenin protein in these cells,`` said Rifat Pamukcu, M.D., Cell Pathways` chief scientific officer. ``It is known that the accumulation of beta-catenin significantly contributes to the growth of colon cancer cells. Within the last year, compelling evidence suggests that beta-catenin may also play an important role in the growth of breast cancer. A recent study from Harvard Medical School in the journal Nature Cell Biology suggests that the over-expression of a protein, Pin1, leads to the over-accumulation of beta-catenin in breast cancer cells by preventing its phosphorylation by another protein, APC. Phosphorylation marks beta-catenin for subsequent destruction by other enzymes. Our studies demonstrate that inhibiting the various cGMP PDE targets in breast cancer cells leads to activation of protein kinase G (PKG) and triggers apoptosis. PKG is capable of phosphorylating beta-catenin, independent of APC, leading to its destruction. This is similar to our findings in colon cancer cells, which we reported in the journal Cancer Research last year.``

The investigators studied the effects of Aptosyn(TM) and CP461 in MDA-MB-435S and HER2/neu over-expressing MDA-MB-453 breast tumor cells. Like colon tumor cells, both breast cancer cell types contained a cGMP specific PDE5, but MDA-MB-435S cells also harbored PDE1 activity. Aptosyn(TM) and CP461, which induce apoptosis in these cells, inhibited cGMP PDEs as confirmed by persistently increased intracellular cGMP levels. Western blots showed a dose-dependent induction of PKG protein by Aptosyn(TM) and CP461 and a concomitant decrease in cellular beta-catenin and cyclin D1.

``Previous presentations have reported synergistic activity between our SAANDs compounds and both Taxotere® and Herceptin® in breast cancer cell lines. Based on our findings to date, we believe that Aptosyn(TM) may someday play an important role in combination with other drug therapies for management of breast cancer,`` said Dr. Pamukcu. He also noted that a Phase I/II clinical trial of Aptosyn(TM) in combination with capecitabine (Xeloda®) in patients with metastatic breast cancer was currently ongoing at M.D. Anderson Cancer Center in Houston, Texas.